UPDATE Citi Lowers Price Target on Incyte to $15
According to Citi, Incyte (NASDAQ: INCY) price target is lowered to $15.
Citi said that it conducted a 25-physician survey in Nov. 2011 on the potential clinical adoption of Jakafi (ruxolitinib) in anticipation of the FDA approval. “On average, physicians expect to prescribe Jakafi in ~35% of their overall MF patients.”
Incyte closed on Friday at $14.24.
(c) 2013 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.